​

Liminatus Pharma Ownership | Who Owns Liminatus Pharma?


OverviewFinancialsChart

Liminatus Pharma Ownership Summary


Liminatus Pharma is owned by 3.98% institutional investors, 33.75% insiders, and 62.27% retail investors. Geode capital management is the largest institutional shareholder, holding 0% of LIMN shares. Fidelity Nasdaq Composite Index is the top mutual fund, with 2.96% of its assets in Liminatus Pharma shares.

LIMN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockLiminatus Pharma3.98%33.75%62.27%
SectorHealthcare Stocks 247.07%12.15%-159.22%
IndustryBiotech Stocks 385.89%11.79%-297.68%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Geode capital management---
Two sigma securities---
Barclays---
Jane street group---
State street---
Virtu financial---
Ubs group---
Stonex group---
Farther finance advisors---
Citigroup---

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Geode capital management---
Two sigma securities---
Barclays---
Jane street group---
State street---
Virtu financial---
Ubs group---
Stonex group---
Farther finance advisors---
Citigroup---

Top Buyers

HolderShares% AssetsChange
Farther finance advisors---14.00
Blackrock funding, inc. /de---313.00
Barclays---4.29K
Citigroup---6.77K
Ubs group---16.73K

Top Sellers

HolderShares% AssetsChange
Geode capital management---138.42K
Jane street group---71.32K
Vanguard capital management---50.44K
Virtu financial---27.47K
Stonex group---26.06K

Sold Out

HolderChange
Farther finance advisors-14.00
Blackrock funding, inc. /de-313.00
Barclays-4.29K
Citigroup-6.77K
Ubs group-16.73K

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202614-6.67%945,955-35.89%310.32%5-54.55%6100.00%
Mar 31, 20261525.00%1,475,438365.15%6348.35%1183.33%350.00%
Dec 31, 20251220.00%317,19321.10%1141.98%6-2100.00%
Sep 30, 202510-261,92427.95%-125.66%6-40.00%1-
Jun 30, 202510-204,702---10---

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Nasdaq Composite Index39.70K2.96%39.70K
Vanguard Institutional Extnd Mkt Idx Tr50.44K0.19%-
Fidelity Extended Market Index2.41K0.18%-
Blackrock Extended Mkt Fund CF12.94K0.05%-
Extended Equity Market Fund E12.94K0.03%-
Extended Equity Market Fund B12.94K0.03%-
BlackRock Extended Equity Market Fund K11.02K0.02%-81.00
NT Ext Equity Mkt Index Fund - Lending4.50K0.02%-
NT Ext Equity Mkt Index Fund - NL3.70K0.01%-
Spartan Total Market Index Pool G3.62K0.01%-

Insider Transactions Trends


DateBuySell
2025 Q2--

LIMN Ownership FAQ


Who Owns Liminatus Pharma?

Liminatus Pharma shareholders are primarily institutional investors at 3.98%, followed by 33.75% insiders and 62.27% retail investors. The average institutional ownership in Liminatus Pharma's industry, Biotech Stocks , is 385.89%, which Liminatus Pharma falls below.

Who owns the most shares of Liminatus Pharma?

Liminatus Pharma’s largest shareholders are Geode capital management (0 shares, 0%), Two sigma securities (0 shares, 0%), and Barclays (0 shares, 0%). Together, they hold 0% of Liminatus Pharma’s total shares outstanding.

Does Blackrock own Liminatus Pharma?

BlackRock is not among the top 10 institutional shareholders of Liminatus Pharma.

Who is Liminatus Pharma’s biggest shareholder by percentage of total assets invested?

Geode capital management is Liminatus Pharma’s biggest shareholder by percentage of total assets invested, with 0% of its assets in 0 Liminatus Pharma shares, valued at 0$.

Who is the top mutual fund holder of Liminatus Pharma shares?

Fidelity Nasdaq Composite Index is the top mutual fund holder of Liminatus Pharma shares, with 2.96% of its total shares outstanding invested in 39.7K Liminatus Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools